Volume 22 Issue 7
Jul.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(7): 1150-1153
LIU Yaning, LI Yan, REN Litao, HOU Xiaoxue, WANG Qian. Effects of bendamustine combined with R-CHOP on the efficacy and safety of diffuse large B-cell lymphoma[J]. Chinese Journal of General Practice, 2024, 22(7): 1150-1153. doi: 10.16766/j.cnki.issn.1674-4152.003587
Citation: LIU Yaning, LI Yan, REN Litao, HOU Xiaoxue, WANG Qian. Effects of bendamustine combined with R-CHOP on the efficacy and safety of diffuse large B-cell lymphoma[J]. Chinese Journal of General Practice, 2024, 22(7): 1150-1153. doi: 10.16766/j.cnki.issn.1674-4152.003587
shu

Effects of bendamustine combined with R-CHOP on the efficacy and safety of diffuse large B-cell lymphoma

doi: 10.16766/j.cnki.issn.1674-4152.003587
  • 1.

    Department of Hematology, Handan First Hospital, Handan, Hebei 056002, China

Funds:

 20231188

  • Received Date: 2023-12-14
    Available Online: 2024-09-05
    Abstract
  •   Objective  To investigate the effects of bendamustine (BEN) combined with rituximab+cyclophosphamide, doxorubicin, vincristine, methylprednisolone (R-CHOP) regimen on the efficacy, serum factors, and adverse reactions in patients with diffuse large B-cell lymphoma (DLBCL).  Methods  A total of 140 DLBCL patients at Handan First Hospital from January 2018 to June 2020 were selected. Using a random number table, they were divided into 2 groups: the control group receiving R-CHOP and the observation group receiving BEN combined with R-CHOP. Their efficacy and safety of the two groups were then compared.  Results  The objective response rate (ORR) of the observation group was higher than that of the control group [85.71% (60/70) vs. 71.43% (50/70), χ2=4.242, P < 0.05]. Post-treatment, levels of carbohydrate antigen 125 (CA125), lactate dehydrogenase (LDH), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and nuclear transcription face-κB p50 (NF-κB p50) in the observation group were lower than those in the control group [(18.34±2.75) U/L vs. (22.54±3.11) U/L, (227.16±35.12) U/L vs. (282.71±37.46) U/L, (75.08±10.76) ng/L vs. (81.29±12.41) ng/L, (17.29±1.81) ng/L vs. (19.16±2.07) ng/L, (976.58±104.08) μg/L vs. (1 137.19±197.65) μg/L, P < 0.05]. There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P>0.05). Furthermore, the cumulative survival rate and progression-free survival rate in the observation group were higher than those in the control group (log-rank χ2=4.243, 3.959, P=0.039, 0.047, respectively).  Conclusion  Combining BEN with R-CHOP improves the short-term and long-term efficacy of DLBCL patients, enhances serum indexes, and ensures safety and effectiveness.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    HE M Y, KRIDEL R. Treatment resistance in diffuse large B-cell lymphoma[J]. Leukemia, 2021, 35(8): 2151-2165. doi: 10.1038/s41375-021-01285-3
    [2]
    WRIGHT G W, HUANG D W, PHELAN J D, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications[J]. Cancer Cell, 2020, 37(4): 551-568. e14. doi: 10.1016/j.ccell.2020.03.015
    [3]
    POLETTO S, NOVO M, PARUZZO L, et al. Treatment strategies for patients with diffuse large B-cell lymphoma[J]. Cancer Treat Rev, 2022, 110: 102443. DOI: 10.1016/j.ctrv.2022.102443.
    [4]
    郭佳丽, 潘晨华, 李依, 等. 弥漫大B细胞淋巴瘤预后相关基因与患者预后及肿瘤浸润性免疫细胞比例的相关性[J]. 山东医药, 2023, 63(3): 33-36. doi: 10.3969/j.issn.1002-266X.2023.03.007

    GUO J L, PAN C H, LI Y, et al. Correlation of independent prognosis-related genes in diffuse large B-cell lymphoma with patients'prognosis and proportion of tumour-infiltrating immune cells[J]. Shandong Medical Journal, 2023, 63(3): 33-36. doi: 10.3969/j.issn.1002-266X.2023.03.007
    [5]
    WANG L, LI L R, YOUNG K H. New agents and regimens for diffuse large B cell lymphoma[J]. J Hematol Oncol, 2020, 13(1): 175. DOI: 10.1186/s13045-020-01011-z.
    [6]
    石磊, 陆敏秋, 高珊, 等. 苯达莫司汀联合化疗方案治疗复发/难治性多发性骨髓瘤的临床观察[J]. 中国医师杂志, 2021, 23(12): 1822-1827. doi: 10.3760/cma.j.cn431274-20210702-00719

    SHI L, LU M Q, GAO S, et al. Clinical reasearch of bendamustine combination regimen in the treatment of relapsed/refractory multiple myeloma[J]. Journal of Chinese Physician, 2021, 23(12): 1822-1827. doi: 10.3760/cma.j.cn431274-20210702-00719
    [7]
    蓝晓凤, 贤晓敏, 刘玄勇, 等. 苯达莫司汀治疗边缘区淋巴瘤的单中心回顾性研究[J]. 中南药学, 2022, 20(7): 1510-1514. https://www.cnki.com.cn/Article/CJFDTOTAL-ZNYX202207006.htm

    LAN X F, XIAN X M, LIU X Y, et al. Efficacy and safety of bendamustine for patients with marginal zone lymphoma: a single center retrospective study[J]. Central South Pharmacy, 2022, 20(7): 1510-1514. https://www.cnki.com.cn/Article/CJFDTOTAL-ZNYX202207006.htm
    [8]
    GHILARDI G, CHONG E A, SVOBODA J, et al. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas[J]. Ann Oncol, 2022, 33(9): 916-928. doi: 10.1016/j.annonc.2022.05.521
    [9]
    中华医学会血液学分会, 中国抗癌协会淋巴瘤专业委员会. 中国弥漫大B细胞淋巴瘤诊断与治疗指南(2013年版)[J]. 中华血液学杂志, 2013, 34(9): 816-819.

    Hematology Branch of Chinese Medical Association, Lymphoma Professional Committee of Chinese Anticancer Association. Chinese guidelines for diagnosis and treatment of difuse large B cell lymphoma (2013)[J]. Chinese Journal of Hematology, 2013, 34(9): 816-819.
    [10]
    MISCHEL A M, ROSIELLE D A. Eastern Cooperative Oncology Group performance status #434[J]. J Palliat Med, 2022, 25(3): 508-510. doi: 10.1089/jpm.2021.0599
    [11]
    ARAS M, ERDIL T Y, DANE F, et al. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors[J]. Nucl Med Commun, 2016, 37(1): 9-15. doi: 10.1097/MNM.0000000000000401
    [12]
    张贵兵, 何正飞, 商文忠, 等. 三乙醇胺对弥漫大B细胞淋巴瘤细胞生物特性的影响[J]. 中华全科医学, 2022, 20(5): 785-788. doi: 10.16766/j.cnki.issn.1674-4152.002454

    ZHANG G B, HE Z F, SHANG W Z, et al. Effect of triethanolamine on the biological characteristics of diffuse large B-cell lymphoma cells[J]. Chinese Journal of General Practice, 2022, 20(5): 785-788. doi: 10.16766/j.cnki.issn.1674-4152.002454
    [13]
    SONG Y, ZHOU H, ZHANG H, et al. Efficacy and safety of the biosimilar IBI301 plus standard CHOP (I-CHOP) in comparison with rituximab plus CHOP (R-CHOP) in patients with previously untreated diffuse large B-Cell lymphoma (DLBCL): a randomized, double-blind, parallel-group, phase 3 trial[J]. Adv Ther, 2021, 38(4): 1889-1903. doi: 10.1007/s12325-020-01603-8
    [14]
    LALIC H, AURER I, BATINIC D, et al. Bendamustine: a review of pharmacology, clinical use and immunological effects (review)[J]. Oncol Rep, 2022, 47(6): 114. DOI: 10.3892/or.2022.8325.
    [15]
    崔玉山, 房佰俊. 苯达莫司汀/马法兰预处理方案可提高接受移植的多发性骨髓瘤患者完全缓解率[J]. 中华医学杂志, 2022, 102(36): 2880.

    CUI Y S, FANG B J. Bendamustine/mafaran preconditioning regimen can improve the complete response rate of multiple myeloma patients receiving transplantation[J]. National Medical Journal of China, 2022, 102(36): 2880.
    [16]
    GERRITY C, MERCADEL A, ALGHAMDI A, et al. Primary ovarian lymphoma: a case report[J]. Gynecol Oncol Rep, 2023, 47: 101212. DOI: 10.1016/j.gore.2023.101212.
    [17]
    SHEN N, YU Y, ZHANG R, et al. Expression and prognostic value of PIK3CA, VEGF, IL-8, IL-10, and RIP2 in diffuse large B-cell lymphoma[J]. Int J Clin Pract, 2022: 2637581. DOI: 10.1155/2022/2637581.
    [18]
    HARTERT K T, WENZL K, KRULL J E, et al. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL[J]. Leukemia, 2021, 35(2): 522-533. doi: 10.1038/s41375-020-0766-4
    [19]
    安立才, 刘英慧, 王婧瑶, 等. 含苯达莫司汀预处理方案自体造血干细胞移植治疗淋巴瘤的近期疗效及安全性[J]. 中华血液学杂志, 2022, 43(1): 63-65. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY202304016.htm

    AN L C, LIU Y H, WANG J Y, et al. Safety and the short-term efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma[J]. Chinese Journal of Hematology, 2022, 43(1): 63-65. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY202304016.htm
    [20]
    熊行芳, 谢晓丽, 王志强, 等. 青蒿琥酯联合苯达莫司汀对弥漫大B细胞淋巴瘤增殖和凋亡的影响[J]. 中国临床药理学杂志, 2023, 39(5): 669-673. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ202305013.htm

    XIONG X F, XIE X L, WANG Z Q, et al. Effects of artesunate combined with bendamustine on proliferation and apoptosis of diffuse large B cell lymphoma[J]. The Chinese Journal of Clinical Pharmacology, 2023, 39(5): 669-673. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ202305013.htm
    [21]
    杜超, 卓秋琪, 罗舟, 等. 苯达莫司汀的药理机制及药动学研究进展[J]. 河北医药, 2021, 43(12): 1883-1888. doi: 10.3969/j.issn.1002-7386.2021.12.031

    DU C, ZHUO Q Q, LUO Z, et al. Research progress on the pharmacological mechanism and pharmacokinetics of bendamustine[J]. Hebei Medical Journal, 2021, 43(12): 1883-1888. doi: 10.3969/j.issn.1002-7386.2021.12.031
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (64) PDF downloads(8) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return